Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Encouraging signs of market recovery with early demand uptick in SDA segment, especially due to hybrid and IC engines. Tatva Chintan expects improved business prospects over the coming quarters with faint signs of market recovery and stable raw material prices.
From Tatva Chintan Pharma Chem Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Encouraging signs of market recovery with early demand uptick in SDA segment, especially due to hybrid and IC engines.
- Commercialisation of all four agro intermediates expected in 2025, contributing to revenue growth.
- New plant at Dahej site to be ready by Q4 FY2026, supporting forecasted demand for agro products.
- Expansion in Phase Transfer Catalysts (PTC) business with two new large MNC customers offering significant volume potential, expected to stabilize over 6-8 months.
- Electrolyte Salts segment showing strong growth momentum, with pilot scale electrolyte formulation scale-up from April 2025.
- Development in semiconductor and electronics chemicals targeting ultra-high purity products expected to become growth drivers in 3 years.
2 more points from Tatva Chintan Pharma Chem Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- A new plant is under construction on the existing Dahej site for agro intermediates, expected to be ready for production in Q4 of FY 2026.
- A new plant is expected to become operational by January 2026 to support future growth and handle full occupancy as the existing plant reaches capacity by June-July 2025.
- Expansion related to the distillation plant started in January to ease production capacities for major products.
- Commercialization of a pharma intermediate product is anticipated by end of 2025 or early 2026 with a fourth product under approval for commercialization by end of next calendar year.
2 more points from Tatva Chintan Pharma Chem Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the exact current or expected order book size in financial terms.
- However, several indications of growing order flow and upcoming commercializations are noted:
- Two large agro intermediates under approval are expected to get final clearance soon, with commercialization starting immediately.
- Four agro intermediates under approval basis are expected to see commercialization during the current year.
- The Phase Transfer Catalyst segment has onboarded two new multinational customers, with commercial business started and volumes expected to ramp up over coming quarters.
- The electrolyte salts segment is gaining momentum, with pilot-scale scale-up planned by April following positive lab results.
2 more points from Tatva Chintan Pharma Chem Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tatva Chintan's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Chemicals & Petrochemicals this season
- Himadri Special (Q3 FY25)
1,131.81 Crs, up 7.53% YoY (from Rs. Key concall takeaways from Himadri Speciality Chemical Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- Gujarat Alkalies (Q3 FY25)
3,702.77 Crores (up from Rs. Key concall takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- Balaji Amines (Q3 FY25)
Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7). Key concall takeaways from Balaji Amines Ltd's Q3…
- Vidhi Specialty (Q3 FY25)
Year-on-Year (Y-o-Y) Growth:** 56.5% increase . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY25 earnings call — and how it ranks…
Arthneeti Pro · Annual
Tatva Chintan Pharma Chem Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q3 FY25 results?
Encouraging signs of market recovery with early demand uptick in SDA segment, especially due to hybrid and IC engines. Tatva Chintan expects improved business prospects over the coming quarters with faint signs of market recovery and stable raw material prices.
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
A new plant is under construction on the existing Dahej site for agro intermediates, expected to be ready for production in Q4 of FY 2026.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.